CORRECTED 10/30/17: The Workers’ Compensation Advisory Council (WCAC) voted to issue a cease and desist letter to Insight Labs regarding pharmacogenetic testing of injured workers in Louisiana. The move follows several months of debate about the practice, which was brought to the attention of the Office of Workers’ Compensation (OWC) by WCAC member Bray Williams. Williams’ client was under the impression that the testing was mandatory given the wording of a letter from Insight Labs. Broadspire has a contract with Insight Labs to perform pharmacogenetic testing. The Council listened to several presenters, including Broadspire and Insight Labs representatives, before the vote. Pharmacogenetic testing itself will not be prohibited by the letter should a Louisiana injured worker’s treating physician choose to request it. Rather, the letter addresses referral practices for the testing (based on urine drug screens), which at least two WCAC members said could be conceived as unauthorized practice of medicine.
Complete coverage from Louisiana Comp Blog here.